Stryker (SYK) Tops Q4 EPS by 16c, Offers FY23 Guidance

Stryker (NYSE: SYK) reported Q4 EPS of $3.00, $0.16 better than the analyst estimate of $2.84. Revenue for the quarter came in at $5.2 billion versus the consensus estimate of $4.96 billion.

GUIDANCE:

Stryker sees FY2023 EPS of $9.85-$10.15, versus the consensus of $9.86.

• As we assess the current operating environment, we believe that there will continue to be macro-economic volatility caused by alleviating supply chain disruptions, inflationary risks and currency fluctuations. Despite the volatile macro-economic environment, we have good momentum in many parts of our business heading into 2023. We expect 2023 organic net sales growth(2) to be in the range of 7.0% to 8.5% and expect adjusted net earnings per diluted share(2) to be in the range of $9.85 to $10.15. Based on the steady progress of our pricing actions, we expect the impact of price to be between 0% and -0.5%. If foreign exchange rates hold near their current levels, we anticipate sales and EPS will be modestly unfavorably impacted as compared to 2022.

For earnings history and earnings-related data on Stryker (SYK) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• ResMed (RMD) Tops Q3 EPS by 20c
• COPT Defense Properties (CDP) Reports In-Line Q1 EPS; offers guidance